Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 2
1(33.3%)
3Total
N/A(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03540420Phase 2Active Not Recruiting

Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer

Role: collaborator

NCT03850171Not ApplicableTerminated

Cancer Adverse Effects PReventIon With Care & Exercise: the CAPRICE Study

Role: collaborator

NCT01039922Recruiting

SwissNET - a Registry for Neuroendocrine Tumours in Switzerland

Role: collaborator

NCT01234428Not ApplicableCompleted

Esophageal Dysmotility and Dilatation After Laparoscopic Gastric Banding

Role: lead

All 4 trials loaded